Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Accumulated Expenses (2020 - 2025)

Oncology Institute's Accumulated Expenses history spans 6 years, with the latest figure at $20.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.15% year-over-year to $20.6 million; the TTM value through Dec 2025 reached $20.6 million, down 2.15%, while the annual FY2025 figure was $20.6 million, 2.15% down from the prior year.
  • Accumulated Expenses reached $20.6 million in Q4 2025 per TOI's latest filing, down from $22.8 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $23.4 million in Q1 2025 to a low of $80000.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $14.6 million, with a median of $14.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 18045.0% in 2022, then dropped 21.21% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $13.9 million in 2021, then increased by 4.82% to $14.6 million in 2022, then fell by 4.1% to $14.0 million in 2023, then skyrocketed by 50.71% to $21.1 million in 2024, then fell by 2.15% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Accumulated Expenses are $20.6 million (Q4 2025), $22.8 million (Q3 2025), and $22.9 million (Q2 2025).